drugset / Trial / NCT02707211
Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases
NaSingle-groupOpen-labelTreatment
Summary
To test whether active pneumococci immunization can alleviate inflammation and improve cholesterol metabolism in lysosomal lipid storage diseases and associated metabolic disorders.
Timeline
- Start
- 2016-06
- Primary completion
- 2017-02
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-oxLDL IgM antibody | Protein / enzyme biologic | — | — |